Luo Simin, Chai Jie, Ding Linxiaoxiao, Tang Song
Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
The Second Department of General Surgery, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China.
Front Pharmacol. 2025 Apr 25;16:1574286. doi: 10.3389/fphar.2025.1574286. eCollection 2025.
Trastuzumab deruxtecan (T-DXd or DS-8201), as a novel antibody-drug conjugate, has demonstrated good efficacy in HER2-positive advanced breast cancer. However, its effectiveness in treating pulmonary lymphangitic carcinomatosis (PLC) has not been previously reported. This paper presents a case of a HER2-positive advanced breast cancer patient who experienced disease progression after treatment with trastuzumab and pertuzumab. The patient developed multiple metastases along with PLC and subsequently received T-DXd treatment, achieving 14.2 months of progression-free survival (PFS). This case is the first to reveal the therapeutic potential of T-DXd in breast cancer patients with PLC.
曲妥珠单抗德曲妥珠单抗（T-DXd或DS-8201）作为一种新型抗体药物偶联物，已在HER2阳性晚期乳腺癌中显示出良好疗效。然而，其治疗肺淋巴管癌病（PLC）的有效性此前尚未见报道。本文介绍了1例HER2阳性晚期乳腺癌患者，该患者在接受曲妥珠单抗和帕妥珠单抗治疗后病情进展。患者出现多处转移并伴有PLC，随后接受T-DXd治疗，无进展生存期（PFS）达14.2个月。该病例首次揭示了T-DXd在伴有PLC的乳腺癌患者中的治疗潜力。
